I found the field of Science & Technology – Other Topics; Materials Science very interesting. Saw the article Antimicrobial Effect of a Novel Chitosan Derivative and Its Synergistic Effect with Antibiotics published in 2021.0. SDS of cas: 61-82-5, Reprint Addresses Chan-Park, MB (corresponding author), Nanyang Technol Univ NTU, Sch Chem & Biomed Engn, Singapore 637459, Singapore.; Chan-Park, MB (corresponding author), Nanyang Technol Univ, Ctr Antimicrobial Bioengn, Singapore 637459, Singapore.; Chan-Park, MB (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 637459, Singapore.; Chan-Park, MB (corresponding author), Nanyang Technol Univ, Sch Phys & Math Sci, Singapore 637459, Singapore.. The CAS is 61-82-5. Through research, I have a further understanding and discovery of 1H-1,2,4-Triazol-5-amine
Cationic polymers are promising antibacterial agents because bacteria have a low propensity to develop resistance against them, but they usually have low biocompatibility because of their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polymer, 2,6-diamino chitosan (2,6-DAC). 2,6-DAC shows excellent broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 8-32 mu g/mL against clinically relevant and multidrug-resistant (MDR) bacteria including Listeria monocytogenes, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Furthermore, 2,6-DAC shows an excellent synergistic effect with various clinically relevant antibiotics proved by decreasing the MICs of the ntibiotics against MDR A. baumannii and methicillin-resistant Staphylococcus aureus to <1 mu g/mL. In vivo biocompatibility of 2,6-DAC is proved by a dosage of 100 mg/kg compound via oral administration and 25 mg/kg compound via intraperitoneal injection to mice; 2,6-DAC does not cause any weight loss and any significant change in liver and kidney biomarkers or the important blood electrolytes. The combinations of 2,6-DAC together with novobiocin and rifampicin show >2.4 log(10) reduction of A. baumannii in murine intraperitoneal and lung infection models. The novel chitosan derivative, 2,6-DAC, can be utilized as a biocompatible broad-spectrum cationic antimicrobial agent alone or in synergistic combination with various antibiotics.
Welcome to talk about 61-82-5, If you have any questions, you can contact Si, ZY; Hou, Z; Vikhe, YS; Thappeta, KRV; Marimuthu, K; De, PP; Ng, OT; Li, P; Zhu, YB; Pethe, K; Chan-Park, MB or send Email.. SDS of cas: 61-82-5
Reference:
Article; Safari, Niloufar; Shirini, Farhad; Tajik, Hassan; Journal of Molecular Structure; vol. 1201; (2020);,
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics